在急性髓性白血病中整合与二硫和铁相关的基因的新型预后特征
Huihui Jiang1, Li Liang2, Tingting Liu1
1Department of Hematology, Qilu Hospital of Shandong University, Jinan, 250012, China.
Clinical and experimental medicine
|August 25, 2025
概括
在急性髓性白血病 (AML) 患者中,结合二硫和铁突变基因的新预后特征准确预测了治疗结果和治疗反应. 这种方法为AML的个性化治疗提供了潜力.
科学领域:
- 血液学
- 癌症学
- 分子生物学
背景情况:
- 急性髓性白血病 (AML) 是一种复杂的血液癌症,患者的结局不同.
- 预测AML的预后和治疗反应仍然是一个临床挑战.
研究的目的:
- 通过整合与二硫和铁相关的基因,开发和验证急性髓性白血病 (AML) 的预后特征.
- 评估该特征能够预测AML患者的预后,免疫治疗反应和药物敏感性.
主要方法:
- 使用TCGA-LAML数据集,使用随机分区进行培训和验证.
- 使用最少绝对收缩和选择操作员 (LASSO) 算法制定了预测风险特征.
- 进行了卡普兰-梅尔生存率,ROC曲线,免疫透和药物敏感性分析;通过qPCR验证了基因表达.
主要成果:
- 开发的风险特征显示出显著的预后准确性,优于现有的特征和突变基因.
- 在高风险和低风险AML群体之间确定了不同的免疫透模式和免疫检查点基因表达.
- 高风险患者对环胺,443654和770041的反应更好;低风险患者对细胞胺和AZD6244的反应更好.
结论:
- 新的预后特征作为AML的独立预测结果.
- 这种特征可以根据AML患者的风险分层来指导个性化的精确治疗选择.
- 需要进一步验证以将这些发现转化为AML治疗的临床实践.
相关概念视频
Differentiation of Common Myeloid Progenitor Cells
3.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84


